Arca
Skip to content
Tools
Tools

TRAF3IP2: E3 ubiquitin ligase TRAF3IP2

E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on TRAF3IP2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 31

    • Iguratimod

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        IguratimodPhase 3EisaiSmall moleculeInhibitorE3 ubiquitin ligase TRAF3IP2 inhibitor6

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
        Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid ArthritisIguratimodNot applicableNot yet recruitingWangjing Hospital, China Academy of Chinese Medical SciencesAug 11, 2025
        Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITPIguratimodPhase 2Not yet recruitingPeking University People's HospitalJul 10, 2025
        A Study of Iguratimod in Combination With Tofacitinib in RA PatientsIguratimodPhase 4Not yet recruitingJie ChangApr 25, 2025
        Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHDIguratimodPhase 1 / Phase 2RecruitingXuzhou Medical UniversityFeb 6, 2024
        Treatment Strategies for IgG4-RD Patients With Superficial Organ InvolvementIguratimodNot applicableRecruitingPeking Union Medical College HospitalMar 29, 2023
        The Clinical Efficacy of Immunomodulators in RA PatientsIguratimodPhase 4RecruitingQilu Hospital of Shandong UniversityNov 23, 2022

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Chronic mucocutaneous candidiasis0.72
        • Psoriasis vulgaris0.54
        • Skin disorder0.45
        • Type 2 diabetes mellitus0.41
        • Neurodegenerative disease0.41
        • Candidiasis, familial, 80.38
        • Discoid lupus erythematosus0.34

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4523586, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O43734, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.